| abstract |
A method for predicting responsiveness to cancer treatment with a compound that inhibits p300, comprising using a biological sample from a cancer patient, detecting the presence or absence of an inactivating mutation in CBP contained in the biological sample, and determining to the patient with the inactivating mutation in CBP detected as sensitive to cancer treatment with the compound that inhibits p300, where the inactivating mutation is a homozygous deletion of CBP, a nonsense mutation of CBP, or one of the mutations Asn83Thr, Ser893Leu, Arg1446Cys, Trp1472Cys, Asn2175Ser, Glu1835Stop, Asn2111Ser, Leu551lle, Gly1411Glu or Ala2044Gly. |